| Management target | Revenue FY28 |
|---|
| Revenue growth | 13% YoY consolidated growth. |
|---|---|
| Margins | Steady gross margin profile expected at 58%-60%. |
| Demand visibility | Strong funnel in UK, Nordics, and Africa. |
| Management confidence | High in Ex-US growth and diversified strategy. |
Growth
Revenue up 13% YoY; Ex-US markets grew 17%. Gross margins improved 14% YoY to 60.9%.
Outlook
Aspirational North America revenue of ~$375m by FY28; focus on nasal sprays and transdermal patches.
Risks
Geopolitical disruptions impacted freight costs by ~₹131m; slower US quota allocations affecting controlled substances.
Last quarter's promises, checked
Delivered
- Gross margins 58%-60% → delivered 60.9% (= BEAT)
- EBITDA margins ~19% → delivered 19.3% (= BEAT)
- Net Debt/EBITDA 1.55x → delivered 1.52x (= BEAT)
Partly delivered
- Sequential Q-on-Q growth → delivered 13% YoY but US growth only 4% (= PARTIAL)
Missed
- US revenue $375m-$400m target → delivered $284m FY26 (= MISS)
Investor Presentation filed with NSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,103.30
- Market cap
- ₹10,169 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.6×Sector 47.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Results Update
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
- Value
- ₹1,265 Cr
Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹165.5 Cr · +56.7% YoY